A Phase 3, Multicenter, open-label, randomized, comparator controlled trial of the safety and efficacy of dalbavancin versus active comparator in pediatric subjects with acute bacterial skin and skin structure infections.

Administered By

Awarded By

Contributors

Start/End

  • October 12, 2020 - March 31, 2022